A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects With Chronic HCV Infection Who Are on Dialysis for End Stage Renal Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 07 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 26 Feb 2018 Planned End Date changed from 1 Oct 2018 to 1 Nov 2018.
- 26 Feb 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Aug 2018.